Wire · opportunities
Kalshi to allow bets on clinical trials, FDA decisions
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
Kalshi, a prediction market platform, has launched betting on clinical trial outcomes and FDA regulatory decisions in partnership with AppliedXL, starting with late-stage trials and initial contracts including Gilead's anito-cel cancer drug and Summit Therapeutics' lung cancer drug. Traders are required to verify employment and cannot hold material nonpublic information.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're a biotech running late-stage trials, your clinical odds are now public and tradeable—which means insider knowledge about your drug's performance just became valuable to hostile traders with deep pockets. You now have a financial adversary with direct interest in your trial stumbling.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics